However, it should be noted that SW982 lacks the hallmark oncogenic fusion protein SS18-SSX and low level of expression of BCL-2 characteristic of SS, thus challenging its utility for preclinical evaluation of novel therapeutics.27 This evidence concerns the gene SSX2 and synovial sarcoma.